Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Lyra Therapeutics (LYRA) Stock Price & Analysis
180 Followers
LYRA Stock Chart & Stats
Day’s Range$3.92 - $4.71
52-Week Range― - ―
Previous Close$4.63
Volume2.44M
Average Volume (3M)N/A
Market Cap
$245.69M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 06, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.33Price Target Upside205.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Lyra Therapeutics News
Ownership Overview
30.89% Insiders
2.63% Mutual Funds
5.33% Other Institutional Investors
61.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Lyra Therapeutics’s market cap?
Currently, no data Available
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 90 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Apr 30, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.262 by -$0.088.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -$0.32.
How many shares outstanding does Lyra Therapeutics have?
Currently, no data Available
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.262. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Among the largest hedge funds holding Lyra Therapeutics’s share is Perceptive Advisors LLC. It holds Lyra Therapeutics’s shares valued at 67M.
---
Lyra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (205.96% Upside)
$12.33 (205.96% Upside)
Blogger Sentiment
Bullish
LYRA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 600.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.23%
12-Months-Change
Fundamentals
Return on Equity
-95.93%
Trailing 12-Months
Asset Growth
50.77%
Trailing 12-Months
Company Description
Lyra Therapeutics
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
---
LYRA Stock 12 Month Forecast
Average Price Target
$12.33
▲(205.96% Upside)
Technical Analysis
Best Analysts Covering LYRA
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
-1.40%
reiterated a buy rating 8 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.40% per trade.
---